N2OFF's 15min chart triggered Bollinger Bands Narrowing, KDJ Death Cross observed.
PorAinvest
viernes, 3 de octubre de 2025, 10:04 am ET1 min de lectura
NITO--
Under the agreement announced on February 25, 2025, N2OFF will purchase 6,622 shares of MitoCareX from SciSparc for $700,000 and exchange the remaining outstanding shares with SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri for N2OFF common stock, representing 40% of N2OFF’s fully diluted capital stock. The sellers will collectively be entitled to 30% of N2OFF’s financing proceeds (capped at $1.6 million) for five years following closing. Additionally, they may receive milestone-based issuances of up to 25% of N2OFF common stock on a fully diluted basis.
N2OFF has committed to financially support MitoCareX’s operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending satisfaction of remaining conditions.
MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031, according to Coherent Market Insights [1].
Separately, the 15-minute chart for N2OFF indicates a narrowing of Bollinger Bands and a KDJ Death Cross on October 3rd, 2025 at 10:00. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.
SPRC--
The 15-minute chart for N2OFF indicates a narrowing of Bollinger Bands and a KDJ Death Cross on October 3rd, 2025 at 10:00. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.
SciSparc Ltd. (NASDAQ:SPRC) stock surged 33% on Tuesday following the approval of the proposed acquisition of SciSparc’s majority-owned subsidiary, MitoCareX Bio Ltd., by N2OFF, Inc. (NASDAQ:NITO). This approval was reached during N2OFF’s special meeting on September 25, 2025, marking a significant milestone in the acquisition process.Under the agreement announced on February 25, 2025, N2OFF will purchase 6,622 shares of MitoCareX from SciSparc for $700,000 and exchange the remaining outstanding shares with SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri for N2OFF common stock, representing 40% of N2OFF’s fully diluted capital stock. The sellers will collectively be entitled to 30% of N2OFF’s financing proceeds (capped at $1.6 million) for five years following closing. Additionally, they may receive milestone-based issuances of up to 25% of N2OFF common stock on a fully diluted basis.
N2OFF has committed to financially support MitoCareX’s operations during the first two years post-closing, including an initial $1 million cash investment. The transaction is expected to close in the first half of October 2025, pending satisfaction of remaining conditions.
MitoCareX focuses on developing novel therapies for hard-to-treat cancers by targeting proteins in the mitochondrial SLC25 protein family. The global cancer therapeutics and biotherapeutics market was valued at approximately $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031, according to Coherent Market Insights [1].
Separately, the 15-minute chart for N2OFF indicates a narrowing of Bollinger Bands and a KDJ Death Cross on October 3rd, 2025 at 10:00. This suggests a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further decreases in the stock price.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios